KEVIN ANTHONY WALTER
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MX000701
Category
Medicine
Type
Written Agreement
Address
Address
Pittsburgh, PA 15213
Personal information
See more information about KEVIN ANTHONY WALTER at radaris.comName
Address
Phone
416 Brookfield Cir, Macungie, PA 18062
4276 Durham Rd, Kintnersville, PA 18930
29 Gerald Ave, Fstrvl Trvose, PA 19053
330 Andrew Cir, Stroudsburg, PA 18360
8706 Perch Ln, Philadelphia, PA 19136
Professional information
See more information about KEVIN ANTHONY WALTER at trustoria.com
Business Analyst At Coventry Health Care
Business Analyst At Coventry Health Care
Position:
Business Analyst at Coventry Health Care
Location:
Greater Pittsburgh Area
Industry:
Insurance
Work:
Coventry Health Care
-
Business Analyst
Kevin Walter, Rochester NY
Kevin Walter, Rochester NY
Work:
University of Rochester
601 Elmwood Ave, Rochester, NY 14642 University of Pittsburgh
200 Lothrop St, Pittsburgh, PA 15213 Department of Neurology School of Medicine University of Uta
50 N Medical Dr, Salt Lake City, UT 84132
601 Elmwood Ave, Rochester, NY 14642 University of Pittsburgh
200 Lothrop St, Pittsburgh, PA 15213 Department of Neurology School of Medicine University of Uta
50 N Medical Dr, Salt Lake City, UT 84132
Brain Endothelial Cell Expression Patterns
Brain Endothelial Cell Expression Patterns
US Patent:
2010006, Mar 11, 2010
Filed:
Nov 11, 2009
Appl. No.:
12/616600
Inventors:
Stephen I. Madden - Sudbury MA, US
Clarence J. Wang - Arlington MA, US
Brian P. Cook - Northboro MA, US
John Laterra - Baltimore MD, US
Kevin Walter - Pittsburgh PA, US
Clarence J. Wang - Arlington MA, US
Brian P. Cook - Northboro MA, US
John Laterra - Baltimore MD, US
Kevin Walter - Pittsburgh PA, US
Assignee:
Genzyme Corporation - Framingham MA
International Classification:
A61K 39/395, C12Q 1/68, C40B 30/04, A61K 39/00, A61P 35/00
US Classification:
4241741, 435 6, 506 9, 4241841
Abstract:
To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECS derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
Brain Endothelial Cell Expression Patterns
Brain Endothelial Cell Expression Patterns
US Patent:
2006012, Jun 15, 2006
Filed:
Aug 15, 2003
Appl. No.:
10/524432
Inventors:
Stephen Madden - Sudbury MA, US
Clarence Cook - Northboro MA, US
Brian Cook - Northboro MA, US
John Laterra - Baltimore MD, US
Kevin Walter - Pittsburgh PA, US
Clarence Cook - Northboro MA, US
Brian Cook - Northboro MA, US
John Laterra - Baltimore MD, US
Kevin Walter - Pittsburgh PA, US
Assignee:
Genzyme Corporation - Framingham
The John Hopkins University - Baltimore MD
The John Hopkins University - Baltimore MD
International Classification:
C12Q 1/68, G01N 33/567, G01N 33/53
US Classification:
435006000, 435007200
Abstract:
To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.